Literature DB >> 21865387

Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5.

Nobuko Ohshima1, Yoshitaka Iba, Ritsuko Kubota-Koketsu, Yoshizo Asano, Yoshinobu Okuno, Yoshikazu Kurosawa.   

Abstract

Influenza A viruses are classified into 16 subtypes according to the serotypes of hemagglutinin (HA). It is generally thought that neutralizing antibodies (Abs) are not broadly cross-reactive among HA subtypes. We examined the repertoire of neutralizing Abs against influenza viruses in humans. B lymphocytes were collected from donors by apheresis, and Ab libraries were constructed by using phage-display technology. Anti-HA clones were isolated by screening with H3N2 viruses. Their binding activity was examined, and four kinds of Abs showing broad strain specificity were identified from one donor. Two of the Abs, F045-092 and F026-427, were extensively analyzed. They neutralized not only H3N2 but also H1N1, H2N2, and H5N1 viruses, although the activities were largely varied. Flow cytometry suggested that they have the ability to bind to HA and HA1 artificially expressed on the cell surface. They show hemagglutination inhibition activity and do not compete with C179, an Ab thought to bind to the stalk region. F045-092 competes with Abs that recognize sites A and B for binding to HA. Furthermore, the serine at residue 136 in site A could be a part of the epitope. Thus, it is likely that F045-092 and F026-427 bind to a conserved epitope in the head region formed by HA1. Interestingly, while the V(H)1-69 gene can encode MAbs against the HA stem that are group 1 specific, F045-092 and its relatives that recognize the head region also use V(H)1-69. The possible epitope recognized by these clones is discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21865387      PMCID: PMC3194982          DOI: 10.1128/JVI.05397-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Antibody fusions with fluorescent proteins: a versatile reagent for profiling protein expression.

Authors:  K Morino; H Katsumi; Y Akahori; Y Iba; M Shinohara; Y Ukai; Y Kohara; Y Kurosawa
Journal:  J Immunol Methods       Date:  2001-11-01       Impact factor: 2.303

2.  Antigenic variants with amino acid deletions clarify a neutralizing epitope specific for influenza B virus Victoria group strains.

Authors:  Naoko Nakagawa; Ritsuko Kubota; Toshimasa Nakagawa; Yoshinobu Okuno
Journal:  J Gen Virol       Date:  2001-09       Impact factor: 3.891

3.  Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120.

Authors:  Chih-chin Huang; Miro Venturi; Shahzad Majeed; Michael J Moore; Sanjay Phogat; Mei-Yun Zhang; Dimiter S Dimitrov; Wayne A Hendrickson; James Robinson; Joseph Sodroski; Richard Wyatt; Hyeryun Choe; Michael Farzan; Peter D Kwong
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

4.  Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system.

Authors:  Y Okuno; K Tanaka; K Baba; A Maeda; N Kunita; S Ueda
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

5.  Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation.

Authors:  D C Wiley; I A Wilson; J J Skehel
Journal:  Nature       Date:  1981-01-29       Impact factor: 49.962

6.  Mapping of antigenic changes in the haemagglutinin of Hong Kong influenza (H3N2) strains using a large panel of monoclonal antibodies.

Authors:  P A Underwood
Journal:  J Gen Virol       Date:  1982-09       Impact factor: 3.891

Review 7.  Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin.

Authors:  J J Skehel; D C Wiley
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

8.  Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid.

Authors:  W Weis; J H Brown; S Cusack; J C Paulson; J J Skehel; D C Wiley
Journal:  Nature       Date:  1988-06-02       Impact factor: 49.962

9.  Organization of human immunoglobulin heavy chain diversity gene loci.

Authors:  Y Ichihara; H Matsuoka; Y Kurosawa
Journal:  EMBO J       Date:  1988-12-20       Impact factor: 11.598

10.  Localization of epitopes recognized by monoclonal antibodies that neutralized the H3N2 influenza viruses in man.

Authors:  Jun Okada; Nobuko Ohshima; Ritsuko Kubota-Koketsu; Yoshitaka Iba; Sayuri Ota; Wakana Takase; Tetsushi Yoshikawa; Toyokazu Ishikawa; Yoshizo Asano; Yoshinobu Okuno; Yoshikazu Kurosawa
Journal:  J Gen Virol       Date:  2010-11-10       Impact factor: 3.891

View more
  67 in total

Review 1.  Traditional and new influenza vaccines.

Authors:  Sook-San Wong; Richard J Webby
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 2.  Influenza virus antigenicity and broadly neutralizing epitopes.

Authors:  Gillian M Air
Journal:  Curr Opin Virol       Date:  2015-04-04       Impact factor: 7.090

Review 3.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

Review 4.  VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design.

Authors:  Fang Chen; Netanel Tzarum; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2019-03-16       Impact factor: 7.090

5.  Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies.

Authors:  Florian Krammer; Natalie Pica; Rong Hai; Irina Margine; Peter Palese
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

6.  Antibody Determinants of Influenza Immunity.

Authors:  James E Crowe
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

7.  B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins.

Authors:  Patrick P Ng; Chiung-Chi Kuo; Stanley Wang; Shirit Einav; Luca Arcaini; Marco Paulli; Carol S Portlock; Joseph Marcotrigiano; Alexander Tarr; Jonathan Ball; Ronald Levy; Shoshana Levy
Journal:  Blood       Date:  2014-01-21       Impact factor: 22.113

8.  Structural Insight into a Human Neutralizing Antibody against Influenza Virus H7N9.

Authors:  Cong Chen; Liguo Liu; Yan Xiao; Sheng Cui; Jianmin Wang; Qi Jin
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

Review 9.  Structural insights into the design of novel anti-influenza therapies.

Authors:  Nicholas C Wu; Ian A Wilson
Journal:  Nat Struct Mol Biol       Date:  2018-02-02       Impact factor: 15.369

Review 10.  Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.

Authors:  Jean-Philippe Julien; Peter S Lee; Ian A Wilson
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.